RxDoctor Payments Data

Staci Stalcup, MD

Family Medicine · Seymour, TNNPI 1487652699

Payments from drug & device makers

$491in general payments, 2019–2025

Across 30 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$152
  • AbbVie$51
  • Pfizer$50
  • Sunovion Pharmaceuticals Inc.$43
  • Johnson & Johnson$36
  • Boehringer Ingelheim$31
  • plus $127 from 6 others

What the payments were for

  • Food & beverage$47296%
  • Education$10%
  • Gifts$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk8$152
AbbVie(2 entities)3$51
Pfizer3$50
Sunovion Pharmaceuticals Inc.4$43
Johnson & Johnson3$36
Boehringer Ingelheim2$31
Amgen2$26
Novartis1$23
Merck1$23
Alkermes, Inc.1$21
Ascend Therapeutics US, LLC1$18
Supernus Pharmaceuticals, Inc.1$17

How this compares

$491 in reported general payments places this provider in the 50th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$121,123
Medicare patients
196
Services billed
2,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$137,903
OzempicSemaglutide84$115,478
JardianceEmpagliflozin85$72,890
XareltoRivaroxaban69$58,657
JanuviaSitagliptin Phosphate53$50,852
MounjaroTirzepatide44$49,522
LinzessLinaclotide70$43,045
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$27,369
FarxigaDapagliflozin Propanediol20$21,229
Tresiba Flextouch U-200Insulin Degludec15$20,710
Repatha SureclickEvolocumab33$20,204
MyrbetriqMirabegron37$19,594
SymbicortBudesonide/Formoterol Fumarate42$12,969
RybelsusSemaglutide11$12,511
Spiriva HandihalerTiotropium Bromide21$10,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro$50$142,425157 claims
Novo NordiskOzempic, Rybelsus$152$127,98995 claims
Boehringer IngelheimJardiance$31$72,89085 claims
Johnson & JohnsonXarelto$36$58,65769 claims
MerckJanuvia$23$50,85253 claims
AbbVieLinzess, Synthroid$51$48,792156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Seymour

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →